Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 14;56(2):77.
doi: 10.3390/medicina56020077.

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea

Renata Marietta Bocskei  1   2 , Martina Meszaros  1 , Adam Domonkos Tarnoki  3 , David Laszlo Tarnoki  3 , Laszlo Kunos  1 , Zsofia Lazar  1 , Andras Bikov  1   4
Affiliations

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea

Renata Marietta Bocskei et al. Medicina (Kaunas). .

Abstract

Background and Objectives: Obstructive sleep apnoea (OSA) is associated with heightened systemic inflammation and a hypercoagulation state. Soluble urokinase-type plasminogen activator receptor (suPAR) plays a role in fibrinolysis and systemic inflammation. However, suPAR has not been investigated in OSA. Materials and Methods: A total of 53 patients with OSA and 15 control volunteers participated in the study. Medical history was taken and in-hospital sleep studies were performed. Plasma suPAR levels were determined by ELISA. Results: There was no difference in plasma suPAR values between patients with OSA (2.198 ± 0.675 ng/mL) and control subjects (2.088 ± 0.976 ng/mL, p = 0.62). Neither was there any difference when patients with OSA were divided into mild (2.134 ± 0.799 ng/mL), moderate (2.274 ± 0.597 ng/mL) and severe groups (2.128 ± 0.744 ng/mL, p = 0.84). There was no significant correlation between plasma suPAR and indices of OSA severity, blood results or comorbidities, such as hypertension, diabetes, dyslipidaemia or cardiovascular disease. Plasma suPAR levels were higher in women when all subjects were analysed together (2.487 ± 0.683 vs. 1.895 ± 0.692 ng/mL, p < 0.01), and also separately in controls (2.539 ± 0.956 vs. 1.411 ± 0.534 ng/mL, p = 0.02) and patients (2.467 ± 0.568 vs. 1.991 ± 0.686 ng/mL, p < 0.01). Conclusions: Our results suggest that suPAR does not play a significant role in the pathophysiology of OSA. The significant gender difference needs to be considered when conducting studies on circulating suPAR.

Keywords: OSAHS; biomarkers; fibrinolysis; inflammation; sleep disordered breathing.

PubMed Disclaimer

Conflict of interest statement

The authors state no conflict of interest. The funders had no role in the design of the study, collection, analyses, interpretation of data, writing of the manuscript or the decision to publish the results.

Figures

Figure 1
Figure 1
Comparison of plasma soluble urokinase-type plasminogen activator receptor (suPAR) levels between patients with OSA and controls. There was no difference between the two groups in plasma suPAR levels (p = 0.62). Mean ± standard deviation is presented.
Figure 2
Figure 2
Comparison of plasma suPAR levels among different disease severities. There was no difference among the groups in plasma suPAR levels (p = 0.87). Mean ± standard deviation is presented.
Figure 3
Figure 3
Comparison of plasma suPAR levels between women and men. Plasma suPAR levels were higher in women in patients with OSA, in controls and when the subjects were analysed together. Mean ± standard deviation is presented.
See this image and copyright information in PMC

References

    1. Kent B.D., Ryan S., McNicholas W.T. Obstructive sleep apnea and inflammation: Relationship to cardiovascular co-morbidity. Respir. Physiol. Neurobiol. 2011;178:475–481. doi: 10.1016/j.resp.2011.03.015. - DOI - PubMed
    1. Horvath P., Tarnoki D.L., Tarnoki A.D., Karlinger K., Lazar Z., Losonczy G., Kunos L., Bikov A. Complement system activation in obstructive sleep apnea. J. Sleep Res. 2018;27:e12674. doi: 10.1111/jsr.12674. - DOI - PubMed
    1. Kunos L., Horvath P., Kis A., Tarnoki D.L., Tarnoki A.D., Lazar Z., Bikov A. Circulating Survivin Levels in Obstructive Sleep Apnoea. Lung. 2018;196:417–424. doi: 10.1007/s00408-018-0120-z. - DOI - PubMed
    1. Pako J., Kunos L., Meszaros M., Tarnoki D.L., Tarnoki A.D., Horvath I., Bikov A. Decreased Levels of Anti-Aging Klotho in Obstructive Sleep Apnea. Rejuvenation Res. 2019 doi: 10.1089/rej.2019.2183. - DOI - PubMed
    1. Bagai K., Muldowney J.A., 3rd, Song Y., Wang L., Bagai J., Artibee K.J., Vaughan D.E., Malow B.A. Circadian variability of fibrinolytic markers and endothelial function in patients with obstructive sleep apnea. Sleep. 2014;37:359–367. doi: 10.5665/sleep.3414. - DOI - PMC - PubMed

Substances

LinkOut - more resources